Yafei Hou

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
36 papers · 2,202 citations · H-index 15

PAPERS

Effects of PKCε knockdown on mitochondrial membrane potential of human glioma cells in vitro and growth of U251 cell-derived tumors in vivo
20231 citationsauthor #3
Abstract B32: T cell receptor-like chimeric antigen-receptor to recognize neoepitopes derived from driver mutations
20220 citationsauthor #1
230 TCR-like chimeric-antigen-receptor to recognize neoepitopes derived from driver mutations
20220 citationsauthor #2
ELMO1 Regulates RANKL-Stimulated Differentiation and Bone Resorption of Osteoclasts
20218 citationsauthor #2
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice
202115 citationsauthor #2
[Progress in functions and mechanisms of immunosuppressive neutrophil subsets: An update].
20200 citationsauthor #6
IMMU-45. CAR-T TREATMENT OF NOVEL MOUSE MODEL OF EGFRVIII+ GBM MIRRORS CLINICAL TRIAL OUTCOMES AND PROVIDES A SYNGENEIC PLATFORM FOR THE INVESTIGATION OF CAR-T MECHANISMS OF ACTION
20190 citationsauthor #4
LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK ssignalling pathway.
201934 citationsauthor #4
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
2018202 citationsauthor #24
Abstract 3767: Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma
20170 citationsauthor #15
IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY
20170 citationsauthor #19
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
201740 citationsauthor #9
Abstract A117: Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
20167 citationsauthor #1
IMST-09. IDENTIFICATION OF A NOVEL H3.3.K27M MUTATION-DERIVED NEOANTIGEN EPITOPE AND CLONING OF A SPECIFIC T-CELL RECEPTOR FOR T-CELL THERAPY IN GLIOMAS
20160 citationsauthor #13
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
201620 citationsauthor #755
IDH mutation-induced suppression of type-1 anti-glioma immune response
20153 citationsauthor #4
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
2014372 citationsauthor #3
Abstract 5017: T-cell repertoire turnover induced by anti-CTLA-4 antibody treatment in cancer patients
20140 citationsauthor #4
Association of maintenance of pre-existing memory T-cell responses following anti-CTLA-4 antibody treatment with improved overall survival.
20142 citationsauthor #4
Effect of anti-CTLA-4 antibody treatment on T-cell repertoire evolution in treated cancer patients.
20131 citationsauthor #2
Induced In Vivo with CTLA-4 Blockade in Diversity of Antigen-Specific Responses
20120 citationsauthor #9
Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
201274 citationsauthor #4
An Autoimmune Response to Odorant Binding Protein 1a Is Associated with Dry Eye in the Aire-Deficient Mouse
201049 citationsauthor #3
Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade.
20102 citationsauthor #5
Identification of an Autoantigen Demonstrates a Link Between Interstitial Lung Disease and a Defect in Central Tolerance
200966 citationsauthor #4
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.
200965 citationsauthor #1
Distinct CD8+ T Cell Repertoires Primed with Agonist and Native Peptides Derived from a Tumor-Associated Antigen1
200842 citationsauthor #1
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
2008260 citationsauthor #4
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
200859 citationsauthor #3
a Tumor-Associated Antigen with Agonist and Native Peptides Derived T Cell Repertoires Primed + Distinct CD 8
20080 citationsauthor #1
Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells
200714 citationsauthor #3
Erratum: (Journal of Experimental Medicine (November 27, 2006) 203: 12 (2727-2735))
20070 citationsauthor #2
CORRECTION
20070 citationsauthor #2
Spontaneous autoimmunity prevented by thymic expression of a single self-antigen
2006281 citationsauthor #2
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
2001588 citationsauthor #2
-deficient Mouse Aire Eye in the Binding Protein 1a Is Associated with Dry an Autoimmune Response to Odorant
year unknown0 citationsauthor #11

TIMELINE

2001 588 citations

2006 281 citations

2007 14 citations

2008 361 citations

2009 131 citations

2010 51 citations

2012 74 citations

2013 1 citations

2014 374 citations

2015 3 citations

2016 27 citations

2017 40 citations

2018 202 citations

2019 34 citations

2020 0 citations

2021 23 citations

2022 0 citations

2023 1 citations

Unknown 0 citations

Yafei Hou

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT